Clinical Trials
2 trialsNCT04300556 2026-06-04
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Phase 1/2 Recruiting
NCT07368985 2026-01-27
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
Erasmus Medical Center
Phase 2 Not yet recruiting